Navigation Links
Preclinical Data Show Alfacell's Onconase Inhibits Tumor Growth of,Non-Small Cell Lung Cancer, Breast Cancer Cells

Poster Presented at AACR Annual Meeting

BLOOMFIELD, N.J., April 16, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that in vivo and in vitro preclinical data presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting show that ONCONASE (ranpirnase) significantly inhibits tumor growth of non-small cell lung cancer (NSCLC) and breast cancer cells.

In the poster titled "Increased apoptosis and reduced lactate levels by ranpirnase in human lung and breast cancer", Intae Lee, Ph.D. and collaborators at the University of Pennsylvania demonstrated that ONCONASE significantly inhibited tumor growth by inducing apoptosis (cell death) in A549 and NCI-H1975 human NSCLC cells and MDA-MB-231 and MCF-7 human breast cancer cells without damaging non-cancerous cells such as HLF-1 human lung fibroblast and NCI/3T3 fibroblast. Additionally, the data indicated that twice weekly injections of ONCONASE were more effective than an equivalent single dose injection in these tumor types.

"The findings of our investigation suggest important potential clinical uses of ONCONASE for the treatment of NSCLC and breast cancer," said Dr. Lee.

Kuslima Shogen, Alfacell's chairman and chief executive officer, added: "This research adds to the extensive published data that supports our continued development of ONCONASE for multiple cancer indications. The ONCONASE franchise includes the gateway indication of malignant mesothelioma and several other tumor types for which we are continuing preclinical and clinical studies."

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death o f cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

     Media Contact:                    Investor Contact:

     David Schull or We
ndy Lau         Andreas Marathovouniotis

     Noonan Russo                      Noonan Russo

     212-845-4271                      212-845-4253

              

     

david.schull@eurorscg.com andreas.marathis@eurorscg.com wendy.lau1@eurorscg.com

CONTACT: Media contacts, David Schull, , or WendyLau, , both at +1-212-845-4271, or Investor Contact,Andreas Marathovouniotis, +1-212-845-4253, or, all of Noonan Russo david.schull@eurorscg.com wendy.lau1@eurorscg.com andreas.marathis@eurorscg.com

Web site: http://www.alfacell.com/

Ticker Symbol: (NASDAQ-NMS:ACEL)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
7. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
11. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... 27, 2016 Kitov ... focused on late-stage drug development, today announced the ... of pivotal batches required for registration of KIT-302 ... This follows Kitov,s announcement in December ... met its primary efficacy endpoint. "We ...
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
(Date:5/25/2016)... HILDEN , Deutschland und GERMANTOWN, ... Zusammenarbeit mit Therawis bedient ... Entscheidungen bei Brustkrebs   QIAGEN N.V. ... QIA) gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung ... prädiktiver Assays für die Onkologie eingegangen zu sein. ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can be time ... preset onto their media," said Christina Austin - CEO of Pixel Film Studios. ... and easily add stylish color grades to their footage. A LUT is a Lookup ...
(Date:5/27/2016)... ... 27, 2016 , ... Southland Log Homes , designer and manufacturer of ... kits, which can be found on its website at SouthlandLogHomes.com. , The designs of ... they highlight the craftsmanship of timber post and beam construction. The result is ...
(Date:5/27/2016)... ... , ... This campaign aims to provide a path to improved education and ... and change. , As nearly 795,000 Americans suffering from a new or recurrent stoke ... with an estimated 129,000 of these people dying from stroke, it’s become our nation’s ...
(Date:5/27/2016)... ... 2016 , ... Aimed at nurses and employees in the health care world, ... in the nursing and health care industry. It also provides insight to the developing ... , As the nursing industry is coming out of one of the biggest ...
(Date:5/26/2016)... ... May 26, 2016 , ... W.S. Badger Co. Inc ., the maker ... 2016 When Work Works Award for its use of effective workplace strategies to increase ... Works project administered by the Families and Work Institute (FWI) and the Society for ...
Breaking Medicine News(10 mins):